Oragenics surges after licensing tech to develop new COVID-19 vaccines

Oragenics

27/07/2021 13:11

** Shares of drug developer  OGEN.A  jump nearly 52% to
$0.95 premarket - set to open at over 4-mth high
    ** OGEN enters licensing agreement with National Research
Council of Canada for technology which could help co to design
and develop next-gen COVID-19 vaccines  urn:newsml:reuters.com:*:nBwbXJJXQa
    ** License enables OGEN to jumpstart animal studies of
vaccine candidates to address original coronavirus as well as
the Beta variant first found in South Africa - Co
    ** Co's lead product is Terra CoV-2, a vaccine candidate to
prevent COVID-19
    ** OGEN had gained 39.3% YTD, up to last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))